Eric Marcotulli is the co-founder of Elysium, a life sciences company developing consumer-facing health products based on aging research. Elysium's first product is Basis, a supplement that increases NAD levels and activates sirtuins, boosting cellular health and longevity.    In the latest episode of Flux we discuss why longevity companies like Sirtris Pharmaceuticals failed, which was initially bought for $720 million in 2008. Eric explains why going direct to consumer is the best strategy and what the current Basis user base looks like. He shares what its like working with eight nobel laureates on his science advisory board and how they decide what product research to pursue. He gets into the importance of bringing peer review rigor to the category, how he plans to build consumer trust, why cellular senescence is a particular area of interest, what his personal health routine is and how he thinks about the singularity.